Page Image

HER2-Positive Breast Cancer

Addition of Palbociclib Shows Benefit in Double-, Triple-Positive Metastatic Breast Cancer
The CDK4/6 inhibitor showed meaningful improvement in HR+, HER+ disease.
Advertisement
Advertisement